文献速递新发突发、热带与寄生虫病

间日疟蚊媒控制感染在无疟疾史受试者中的安全性与分子诊断价值

Safety and Tolerability of Mosquito Bite-Induced Controlled Human Infection with Plasmodium vivax in Malaria-Naive Study Participants-Clinical Profile and Utility of Molecular Diagnostic Methods.
PubMed 文献 · J Infect Dis · 2022-01-01

本研究报道了蚊媒接种间日疟控制人类感染(PvCHMI)在无疟疾史受试者中的临床与实验室数据,不良事件为轻至中度且无研究相关严重不良事件。分子诊断方法在显微镜确诊前100%检出寄生虫血症,多数症状在治疗后出现,提示PvCHMI安全且敏感分子方法有助于早期诊断。

要点

  • PvCHMI在无疟疾史受试者中不良事件为轻至中度,无研究相关严重不良事件。
  • 分子诊断在显微镜确诊前100%检出寄生虫血症,qPCR和qRT-PCR较显微镜更早预警症状。
  • 多数症状在治疗开始后出现,可能为药物相关反应。

核心结论

  • 蚊媒接种间日疟控制人类感染在无疟疾史受试者中安全性良好,不良事件为轻至中度且无研究相关严重不良事件。

研究设计与样本

  • 报告蚊媒接种间日疟控制人类感染后无疟疾史受试者的临床与实验室数据,包括血液学、生化指标及不良事件。
  • 疟疾诊断与治疗启动基于吉姆萨染色血涂片显微镜检查,探索性分子检测采用实时聚合酶链反应(PCR)。

主要发现

  • 不良事件为轻至中度,任何受试者均未观察到研究相关严重不良事件,多数症状为一过性并在48小时内缓解。
  • 分子诊断方法在显微镜诊断疟疾前100%检出受试者寄生虫血症。
  • 在症状出现前,显微镜检出67%-100%、定量PCR检出79%-100%、定量实时逆转录PCR检出96%-100%的受试者不良事件。
  • 几乎所有症状在治疗开始后出现,可能为已知的药物相关后果。

关键数值与推荐

  • 分子诊断在显微镜诊断前100%检出寄生虫血症。
  • 症状出现前不良事件检出率:显微镜67%-100%,定量PCR79%-100%,定量实时逆转录PCR96%-100%。

临床怎么用

  • PvCHMI可作为评估药物、疫苗及间日疟相关病理的工具,在无疟疾史受试者中安全性可控。
  • 采用敏感分子诊断方法可在临床症状出现前检测寄生虫血症,有助于早期临床诊断和干预。

局限性

  • PvCHMI实施数量有限,安全性数据较少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Plasmodium vivax controlled human malaria infection (PvCHMI) is an important tool for evaluation of drugs, vaccines, and pathologies associated with this parasite. However, there are few data on safety due to limited numbers of PvCHMIs performed. METHODS: We report clinical and laboratory data, including hematological and biochemical profiles and adverse events (AEs), following mosquito bite-induced PvCHMI in malaria-naive study participants. Malaria diagnosis and treatment initiation was based on microscopic analysis of Giemsa-stained slides. Exploratory molecular assays were used to detect parasites using real-time polymerase chain reaction (PCR). RESULTS: AEs were mild to moderate and no study-related severe AEs were observed in any study participants. The majority of symptoms were transient, resolving within 48 hours. Molecular diagnostic methods detected parasitemia in 100% of study participants before malaria diagnosis using microscopy. Of reported AEs, microscopy detected 67%-100%, quantitative PCR 79%-100%, and quantitative real-time reverse-transcription PCR 96%-100% of study participants prior to appearance of symptoms. Almost all symptoms appeared after initiation of treatment, likely as known consequence of drug treatment. CONCLUSIONS: PvCHMI is safe with the majority of infections being detected prior to appearance of clinical symptoms, which can be further alleviated by using sensitive molecular methods for clinical diagnosis. Clinical Trials Registration. NCT01157897.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Kamau E, Bennett JW, Yadava A, et al. Safety and Tolerability of Mosquito Bite-Induced Controlled Human Infection with Plasmodium vivax in Malaria-Naive Study Participants-Clinical Profile and Utility of Molecular Diagnostic Methods. J Infect Dis. 2022. PMID: 34161579. doi:10.1093/infdis/jiab332

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。